A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

NCT ID: NCT01604863

Last Updated: 2012-11-01

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE1
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2014-07-31

Brief Summary

The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.

Detailed Description

This study will consist of 3 regimens each containing 2 dose levels of HGS1036 and full dose chemotherapy. Patients will be treated in sequence with HGS1036 at planned dose levels of 10 mg/kg and 20 mg/kg. Patients who demonstrate stable disease or better may continue to receive HGS1036 until progressive disease, unacceptable toxicity, patient requests discontinuation of study treatment, or the Investigator feels further treatment is not in the patient's best interest. After discontinuation of HGS1036, subjects will be followed for 30 days after the last dose of HGS1036 for safety. The end of study will be defined as 1 year after the last subject begins treatment of HGS1036. Any subject still receiving HGS1036 at this pre-defined end of study, may continue to receive HGS1036, but the only study assessments required will be for safety.

Conditions

Cancer

Keywords

Solid Tumors; Cancer; Lung Cancer; Prostate Cancer; Mesothelioma; Small Cell lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

HGS1036 + Paclitaxel + Carboplatin

Group Type: EXPERIMENTAL

HGS1036 + Paclitaxel + Carboplatin

Intervention Type: DRUG

HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.

Arm B

HGS1036 + Cisplatin + Etoposide

Group Type: EXPERIMENTAL

HGS1036 + Cisplatin + Etoposide

Intervention Type: DRUG

HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.

Arm C

HGS1036 + Docetaxel

Group Type: EXPERIMENTAL

HGS1036 + Docetaxel

Intervention Type: DRUG

HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.

Interventions

HGS1036 + Paclitaxel + Carboplatin

HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.

Intervention Type: DRUG

HGS1036 + Cisplatin + Etoposide

HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.

Intervention Type: DRUG

HGS1036 + Docetaxel

HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Have a histological or cytological diagnosis of malignant solid neoplasm requiring systemic chemotherapy.
• Age ≥18 years.
• ECOG performance status 0-1.
• Adequate organ function.
• Adequate hematological function.
• Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.
• Consent to collection of previously obtained, archival biopsy or surgical specimens of the currently treated malignancy when available.

Exclusion Criteria

• Significant cardiac disease.
• Eye trauma or disease.
• Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months prior to first dose of HGS1036.
• Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of HGS1036.
• Major surgery within 4 weeks of the first dose of HGS1036.
• Prior organ or allogeneic stem cell transplant.
• Non-healing or chronic wounds.
• Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036.
• Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of the first dose of HGS1036.
• Active CNS involvement by primary or metastatic tumor.
• Documented active infection requiring the use of systemic antibiotics.
• Pregnancy or lactation.
• Known HIV-positive serology, AIDS, or an AIDS-related illness.
• Conditions likely to increase the potential for abdominal perforation or fistula formation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Human Genome Sciences Inc., a GSK Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Scottsdale, Arizona, United States

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

HGS1036-C1118

Identifier Type: -

Identifier Source: org_study_id